ReNeuron Group PLC (LON:RENE)

ReNeuron Group PLC (LON:RENE)


Share Price
205.00 p
Change
0 (0.00 %)
Market Cap
£65.19 m
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC RNS Release

Director/PDMR Shares and Share Options


RNS Number : 8054V
ReNeuron Group plc
10 April 2019
 

 

 

10 April 2019

AIM: RENE

ReNeuron Group plc

 

Director/PDMR Interest in Shares and Share Options

 

 

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that the following share option grants were made today under the Company's Long Term Incentive Plan (the "Plan"), its US Incentive Stock Option Plan (the "US Plan") and its Non-Executive Share Option Scheme to directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below.

 

The Plan allows the Company to grant tax-advantaged share options under a Company Share Option Plan (the "CSOP Plan"), as well as non-tax advantaged options.  Where capacity exists for a director/PDMR to be issued share options under the CSOP Plan, these options are issued in parallel with non tax-advantaged options.  The figures per individual below, where applicable and except where indicated, therefore comprise parallel grants of both CSOP Plan share options and non tax-advantaged share options, the terms of each grant ensuring that the exercise of one type of option reduces the number exercisable under the other type of option on a share for share basis. Individuals can therefore elect, subject to their tax status, which specific option grant (CSOP or non tax-advantaged options) they exercise.

The Plan also allows the Company to grant Incentive Stock Options ("ISOs") under the US Plan, as well as a conditional right to receive shares ("Conditional Rights") to employees in the US. Where a US employee is issued ISOs under the US Plan, these options are issued in parallel with Conditional Rights. The figures per individual below, where applicable and except where indicated, therefore comprise parallel grants of both ISOs and Conditional Rights, the terms of each grant ensuring that the exercise of one type of option or right reduces the number that vest under the other type of option or right on a share for share basis. The Conditional Rights are granted at nominal value and the ISOs have an exercise price of 222 pence per share being the closing price of the Company's shares on 09 April 2019.

Share options granted under the CSOP Plan are over shares up to an aggregate market value of £30,000 (measured at the date of grant) and with an exercise price of 222 pence per share, being the closing mid-market price of the Company's shares on 09 April 2019.  Non tax-advantaged options are granted at nominal value.

 

Share options granted under the Plan and the US Plan (unless otherwise stated) are exercisable from the third anniversary of the award and are subject to the achievement of the following performance conditions:

 

1)    When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest.

2)    When the Company's share price has doubled from the price at the date of grant, one third of the options will vest.

3)    When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.

 

The Non-Executive Directors of the Company are remunerated partly in cash and partly in the form of share options granted under the Non-Executive Share Option Scheme.  In order to remove as far as possible any incentive element that might influence the Non-Executive Directors' independence, share options are granted at nominal value without performance conditions attaching and vest over three years on a straight line basis.

 

Share option grants are deemed accepted by the option holder unless expressly rejected within a period of 30 days from the date of grant.

 

 

Name

Title

Date of grant of  share options (i)

Number of share options granted

 

Total shares over which options are held (post award)

Percentage of issued shares under option

Richard Beckman(ii)

Chief Medical Officer

10 April 2019

146,946

300,528

0.95%

John Berriman

Non-executive Chairman

10 April 2019

6,000

54,252

0.17%

Simon Cartmell

Non-executive Director

10 April 2019

6,000

54,252

0.17%

Tim Corn

Non-executive Director

10 April 2019

6,000

47,452

0.15%

Randolph Corteling

Head of Research

10 April 2019

36,800

190,301

0.60%

Claudia D'Augusta

Non-executive Director

10 April 2019

6,000

28,700

0.09%

Chris Evans

Non-executive Director

10 April 2019

6,000

41,700

0.13%

Sharon Grimster

VP Development & General Manager - Wales

10 April 2019

70,000

318,821

1.01%

John Hawkins (iii)

Financial Controller

10 April 2019

20,000

40,000

0.13%

Olav Hellebo

Chief Executive Officer

10 April 2019

260,861

1,066,721

3.37%

Michael Hunt

Chief Financial Officer

10 April 2019

103,785

556,002

1.76%

Mike Owen

Non-executive Director

10 April 2019

6,000

31,700

0.10%

Shaun Stapleton

Head of Regulatory Affairs

10 April 2019

58,000

275,897

0.87%

Paula Thornton(iii)

HR Director

10 April 2019

12,000

20,000

0.06%

 

(i) The option grants are under the non-tax advantaged scheme and (where capacity exists) the CSOP Plan (as detailed above) save for (ii) below, which has been granted under the US Plan, and the Non-Executive Directors' grants.

 

(ii) The grant to Dr Beckman includes the grant of ISOs under the US Plan and Conditional Rights under The Plan. These options or rights are exercisable subject to achievement of performance conditions (1) to (3) above.  The ISOs and Conditional Rights vest from the second anniversary of grant onwards, the ISOs being subject to an annual $100,000 limit based on the aggregate fair value of shares subject to grant measured on the date of grant. 

 

(iii) The grants to Mr Hawkins and Mrs Thornton are made under The Plan and are exercisable subject to achievement of performance conditions (1) and (3) above, with 50% of the options becoming exercisable in each case.

 

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

 

 

ENDS

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø , Chief Executive Officer

 

Michael Hunt, Chief Financial Officer

 

 

Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Tilly Abraham

 

 

 

 

Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

 

 

Nplus1 Singer Advisory LLP

+44 (0) 20 7496 3000

Mark Taylor (Joint Broker)

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 (Disclosure in relation to share options granted to Directors and PDMRs)

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Berriman

2

Reason for the notification 

a)

Position/status 

Non-Executive Chairman

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

6,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Beckman

2

Reason for the notification 

a)

Position/status 

Chief Medical Officer

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options and conditional rights

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

146,946

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Simon Cartmell

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

6,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Tim Corn

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

6,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Randolph Corteling

2

Reason for the notification 

a)

Position/status 

Head of Research

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

36,800

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Claudia D'Augusta

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

6,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Chris Evans

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

6,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sharon Grimster

2

Reason for the notification 

a)

Position/status 

VP Development & General Manager - Wales

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

 

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

70,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Hawkins

2

Reason for the notification 

a)

Position/status 

Financial Controller

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

20,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Olav Hellebo

2

Reason for the notification 

a)

Position/status 

Chief Executive Officer

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

260,861

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Hunt

2

Reason for the notification 

a)

Position/status 

Chief Financial Officer

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

103,785

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mike Owen

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

6,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Shaun Stapleton

2

Reason for the notification 

a)

Position/status 

Head of Regulatory Affairs

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

58,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Paula Thornton

2

Reason for the notification 

a)

Position/status 

HR Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

1p

12,000

 

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

Granted 10 April 2019

f)

Place of the transaction 

Outside a trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFMGMDFGFGLZM

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use